![Reijer Lenstra](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Reijer Lenstra
Plus aucun poste en cours
Finance
Profil
Dr. Lenstra received a Bachelors (BS) in Medicine from the University of Utrecht, The Netherlands in 1977, a Bachelors (BS) in Chemistry from the University of Utrecht, The Netherlands in 1981, a Masters (MS) in Chemistry from the University of Utrecht, The Netherlands in 1983, a Ph.D.
Molecular Biology from the University of Paris VII, France in 1988 and an MBA from Columbia University, New York in 1992
Anciens postes connus de Reijer Lenstra
| Sociétés | Poste | Fin |
|---|---|---|
BioPharma Management Co. Ltd.
 BioPharma Management Co. Ltd. Investment ManagersFinance BioPharma invests primarily in smaller innovative companies that develop medical devices, drugs or pharmaceuticals using modern biotechnology research. They may also invest in larger companies that operate in the related traditional pharmaceutical and medical device areas. Investment decisions are based on fundamental analysis and on integration of information, knowledge, experience and expertise concerning medical and financial aspects of biopharma companies. The firm's investment scope is worldwide, and they invest primarily in equities (or equity related securities) admitted to official listing on a stock exchange or trading on another well recognized regulated market that operates regularly and is open to the public. BioPharma performs proprietary research upon which their investment strategies are based. The investment selection process starts with a top-down analysis of medical research by medical specialty or disease. A second step in the investment selection process involves a financial analysis of the market opportunity for promising new drugs. In the third step of the investment selection process, BioPharma analyzes the financials of the biotechnology companies that are developing and or selling promising drugs. This company-specific analysis results in projections of future profits and the calculation of fair values for the company and its stock. Such fair values are compared with fair values of similar and competing companies. Those stocks that seem to be fairly priced compared to others (or fairly priced on an absolute basis) are then selected for the portfolio. The firm does not track any benchmarks or known biotech indexes. | Directeur en chef des Investissements | 30/06/2007 |
Smith Barney, Inc.
 Smith Barney, Inc. Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 07/10/1997 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
BioPharma Management Co. Ltd.
BioPharma Management Co. Ltd. Investment ManagersFinance BioPharma invests primarily in smaller innovative companies that develop medical devices, drugs or pharmaceuticals using modern biotechnology research. They may also invest in larger companies that operate in the related traditional pharmaceutical and medical device areas. Investment decisions are based on fundamental analysis and on integration of information, knowledge, experience and expertise concerning medical and financial aspects of biopharma companies. The firm's investment scope is worldwide, and they invest primarily in equities (or equity related securities) admitted to official listing on a stock exchange or trading on another well recognized regulated market that operates regularly and is open to the public. BioPharma performs proprietary research upon which their investment strategies are based. The investment selection process starts with a top-down analysis of medical research by medical specialty or disease. A second step in the investment selection process involves a financial analysis of the market opportunity for promising new drugs. In the third step of the investment selection process, BioPharma analyzes the financials of the biotechnology companies that are developing and or selling promising drugs. This company-specific analysis results in projections of future profits and the calculation of fair values for the company and its stock. Such fair values are compared with fair values of similar and competing companies. Those stocks that seem to be fairly priced compared to others (or fairly priced on an absolute basis) are then selected for the portfolio. The firm does not track any benchmarks or known biotech indexes. | Finance |
Smith Barney, Inc.
Smith Barney, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
